Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Interest & Investment Income of $36000.0 for Q1 2026, up 2.86% year-over-year from $35000.0 in Q1 2025, and up 44.0% quarter-over-quarter from $25000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 2.86% year-over-year to $36000.0; the TTM figure through Mar 2026 stood at $126000.0 (down 56.85% YoY), while the FY2025 annual figure was $126000.0, down 62.72% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $36000.0, up from $25000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $93000.0 in Q3 2024, with the low at $1000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $39000.0 (2025), against an average of $45882.4.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 4300.0% in 2023, then plunged 70.24% in 2025.
- Galectin Therapeutics' Interest & Investment Income stood at $30000.0 in 2022, then soared by 146.67% to $74000.0 in 2023, then advanced by 13.51% to $84000.0 in 2024, then slumped by 70.24% to $25000.0 in 2025, then jumped by 44.0% to $36000.0 in 2026.
- Business Quant data shows GALT's Interest & Investment Income at $36000.0 in Q1 2026, $25000.0 in Q4 2025, and $39000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Galectin Therapeutics | 303.35 Mn | 303.35 Mn | - | 28,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |